Navigation Links
Toward making 'extended blood group typing' more widely available
Date:7/14/2010

Scientists are reporting an advance toward enabling more blood banks to adopt so-called "extended blood group typing," which increases transfusion safety by better matching donors and recipients. Their report on a new, automated genetic method for determining a broader range of blood types appears in ACS' Analytical Chemistry, a semi-monthly journal.

Christophe Marquette and colleagues explain that most blood banks still use a century-old blood approach to blood typing. It identifies blood group antigens on red blood cells -- proteins that must match in donor and recipient to avoid potentially serious transfusion reactions. Most blood currently is typed for only a few of the 29 known human blood groups, even though some rare blood groups can affect the outcome of a transfusion. Commercial technology does exist for extended typing with DNA tests. However, it is expensive, difficult to use, and suited more for research labs than high-volume blood centers, they state. Wide adoption of extended blood group typing, they note, requires a test that can handle the high volume of blood processed each year -- 14 million donations in the United States, for instance, and 20 million in Europe.

The study describes evaluation of the new more affordable method, called the HiFi Blood 96, which types blood with DNA testing in a high-speed automated procedure. Tests on 293 human blood samples demonstrated the performance and reliability of the new method. The report compares HiFi Blood 96 to existing commercial tests, and discusses improvements that are underway.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. Scientists locate oil plume extending toward Dry Tortugas
2. International panel recommends redirecting the world community toward sustainable growth
3. Scientists make important step toward stopping plaque-like formations in Huntingtons disease
4. New steps toward a universal flu vaccine
5. Toward simplifying treatment of a serious eye infection
6. Toward a urine test for detecting colon cancer
7. Congress takes another stride toward public access to research
8. Metabolic fingerprints offer fresh clues and a new path toward personalized medicine
9. Toward safer plastics that lock in potentially harmful plasticizers
10. An electrifying advance toward tomorrows power suits
11. Discovery points toward anti-inflammation treatment for blinding disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Toward making 'extended blood group typing' more widely available
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics ... Awards. uBiome is one of just six company finalists in the Health & ... to uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... SEOUL, South Korea , Dec. 8, 2016 /PRNewswire/ ... completed a $21 billion KRW (US $18.9M) Series A ... Management, Kolon Investment, G.N. Tech Venture and SNU Bio ... by Eutilex to 30.5 billion KRW (US $27.7M) since ... will help Eutilex to bolster the development and commercialization ...
(Date:12/7/2016)... ... December 07, 2016 , ... ACEA Biosciences, Inc. presented ... expansion clinical trial for its lead drug candidate, AC0010, at the World Conference ... was to determine the safety, antitumor activity, and recommended phase II dosage of ...
Breaking Biology Technology: